Leflunomide: friend or foe for systemic lupus erythematosus?

被引：21

作者：

Wu, Guo-Cui ^{[1
]}

Xu, Xiao-Di ^{[1
]}

Huang, Qiong ^{[1
]}

Wu, Hua ^{[1
]}

机构：

[1] First Peoples Hosp Hefei City, Dept Pharm, Binhu Hosp, Hefei 230001, Anhui, Peoples R China

来源：

RHEUMATOLOGY INTERNATIONAL | 2013年 / 33卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Leflunomide; Systemic lupus erythematosus; Therapy; ACUTE INTERSTITIAL PNEUMONIA; ACTIVE RHEUMATOID-ARTHRITIS; PERIPHERAL NEUROPATHY; DOUBLE-BLIND; KAPPA-B; METHOTREXATE; EFFICACY; PLACEBO; SAFETY; DRUG;

D O I：

10.1007/s00296-012-2508-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.

引用

页码：273 / 276

页数：4

共 37 条

[21] Kessel Aharon, 2002, Harefuah, V141, P355
[22] Leflunomide suppresses TNF-induced cellular responses:: Effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis
Manna, SK
Mukhopadhyay, A
Aggarwal, BB
[J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (10) : 5962 - 5969
[23] Manna SK, 1999, J IMMUNOL, V162, P2095
[24] Petera P, 2000, ARTHRITIS RHEUM, V43, pS241
[25] Petri M, 2001, ARTHRITIS RHEUM, V44, pS280
[26] THE USE OF THE MURINE CHRONIC GRAFT VS HOST (CGVH) DISEASE, A MODEL FOR SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE), FOR DRUG DISCOVERY
POPOVIC, S
BARTLETT, RR
[J]. AGENTS AND ACTIONS, 1987, 21 (3-4): : 284 - 286
[27] Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study
Remer, CF
Weisman, MH
Wallace, DJ
[J]. LUPUS, 2001, 10 (07) : 480 - 483
[28] Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial
Smolen, JS
Kalden, JR
Scott, DL
Rozman, B
Kvien, TK
Larsen, A
Loew-Friedrich, I
Oed, C
Rosenburg, R
[J]. LANCET, 1999, 353 (9149) : 259 - 266
[29] Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story
Smolen, JS
Graninger, WB
Emery, P
[J]. RHEUMATOLOGY, 2000, 39 (07) : 689 - 692
[30] Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis
Soliotis, F
Glover, M
Jawad, ASM
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) : 850 - 851

← 1 2 3 4 →